WTO TRIPS Waiver Alone Insufficient to Ensure Global Access to COVID-19 Medicines, Experts Warn

The COVID-19 pandemic has once again underscored the tension between intellectual property rights and public health imperatives. Patents and other exclusive rights provide pharmaceutical companies with necessary monopolies to recoup substantial investments in drug development. These protections extend beyond medicines to include critical technologies such as copyright-protected virus-tracing software.

However, the monopoly power granted by intellectual property rights enables companies to set high prices, potentially limiting access to essential COVID-19 treatments. This pricing concern is particularly acute given that over US$12 billion in public funding supported the research and development of the six authorized COVID-19 vaccines.

In response, there have been calls for voluntary licensing pledges from patent holders to facilitate broader access. The World Health Organization (WHO) launched a voluntary patent pool aimed at sharing rights for manufacturing vaccines, therapeutics, and diagnostics.

More assertively, South Africa and India, backed by numerous developing nations facing difficulties in obtaining affordable COVID-19 technologies, proposed a waiver of certain provisions of the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). This waiver, still under negotiation, would permit countries to produce and use COVID-19-related technologies without fear of infringing intellectual property rights, with the measure intended to be temporary.

The proposal has met resistance from developed countries including the United States, Canada, the European Union, and the United Kingdom, which seek to protect their pharmaceutical sectors.

Critically, experts argue that even if adopted, the TRIPS waiver may not suffice to ensure timely access to medicines in many developing countries. Implementing the waiver would require swift amendments to national laws, a process that could be complex or unfeasible for some jurisdictions.

Moreover, existing TRIPS flexibilities such as compulsory licensing and parallel imports are often cited as alternatives. Yet, the compulsory licensing mechanism designed for countries lacking manufacturing capacity has proven cumbersome and underutilized, having been invoked only once since 2003—in 2007, when Canada issued a compulsory license to supply AIDS drugs to Rwanda.

Additional barriers persist beyond intellectual property rights. Bilateral trade agreements, particularly those involving the US and EU, often restrict generic manufacturers’ ability to produce and distribute affordable medicines. For instance, these agreements may limit parallel imports, which allow countries to import cheaper versions of patented drugs from other markets.

Furthermore, provisions known as “patent linkage” in certain free trade agreements prevent drug regulatory authorities from approving generics while the original product remains patented. Countries party to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), including Brunei, Chile, Malaysia, Mexico, Peru, and Vietnam, are subject to such rules.

Other trade agreements impose data exclusivity requirements, granting absolute protection to clinical test data submitted for regulatory approval. This exclusivity bars generic manufacturers from relying on existing data to obtain marketing authorization, delaying the introduction of lower-cost alternatives. Nations such as Morocco, Jordan, El Salvador, Guatemala, Honduras, and Nicaragua have adopted these protections through agreements with the US.

Given these multifaceted challenges, some leaders, including French President Emmanuel Macron and British Prime Minister Boris Johnson, have advocated for enhanced vaccine sharing rather than relying solely on IP waivers.

The COVAX initiative, led by the WHO, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations, aims to distribute over two billion vaccine doses to 190 countries by the end of 2021, representing a significant effort to improve global access.

This conflict between intellectual property protection and access to essential medicines is not new. In 1998, pharmaceutical companies legally challenged South Africa’s attempts to enact laws facilitating affordable access to HIV/AIDS treatments, arguing such measures undermined patent rights.

The current debate over the TRIPS waiver and alternative approaches reflects the ongoing struggle to balance innovation incentives with urgent public health needs during a global crisis.